Novel glucocorticoids: Where are we now and where do we want to go?

Clinical and Experimental Rheumatology

Volumn 33, Issue , 2015, Pages 29-33

  Buttgereit, Frank ^a   Spies, C M ^a   Bijlsma, J W J ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Benefit:risk ratio; Glucocorticoid therapy; Liposomal glucocorticoids; Modified release prednisone; Selective glucocorticoid receptor agonists

Indexed keywords

DIPYRIDAMOLE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FOSDAGROCORAT; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; LIPOSOMAL GLUCOCORTICOID; MEMBRANE BOUND GLUCOCORTICOID RECEPTOR; NCX 1015; NITROSTEROID; PLACEBO; PREDNISOLONE; PREDNISONE; SELECTIVE GLUCOCORTICOID RECEPTOR AGONIST; TRIPTERYGIUM WILFORDII EXTRACT; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; DRUG COMBINATION; LIGAND; LIPOSOME;

ARTICLE; COMBINATION CHEMOTHERAPY; CORTICOSTEROID THERAPY; DAS28; DELAYED RELEASE FORMULATION; DRUG APPROVAL; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; EUROPE; HUMAN; MODIFIED RELEASE FORMULATION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; UNITED STATES; UNSPECIFIED SIDE EFFECT; AGONISTS; ANIMAL; CHRONOTHERAPY; DRUG COMBINATION; DRUG DEVELOPMENT; DRUG EFFECTS; IMMUNOLOGY; INFLAMMATION; MEDICINAL CHEMISTRY; METABOLISM; MOLECULARLY TARGETED THERAPY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CHEMISTRY, PHARMACEUTICAL; DRUG CHRONOTHERAPY; DRUG COMBINATIONS; DRUG DISCOVERY; GLUCOCORTICOIDS; HUMANS; INFLAMMATION; LIGANDS; LIPOSOMES; MOLECULAR TARGETED THERAPY; RECEPTORS, GLUCOCORTICOID; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84953342215     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. BUTTGEREIT F: Do the treatment with glucocorticoids and/or the disease itself drive the impairment in glucose metabolism in patients with rheumatoid arthritis? Ann Rheum Dis 2011; 70: 1881-3.
2. BUTTGEREIT F, BURMESTER GR, STRAUB RH et al.: Exogenous and endogenous glucocorticoids in rheumatic diseases. Arthritis Rheum 2011; 63: 1-9.
3. RHEN T, CIDLOWSKI JA: Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N Engl J Med 2005; 353: 1711-23.
4. STREHL C, BUTTGEREIT F: Optimized glucocorticoid therapy: Teaching old drugs new tricks. Mol Cell Endocrinol 2013; 380: 32-40.
5. BUTTGEREIT F, da SILVA JA, BOERS M et al.: Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis 2002; 61: 718-22.
6. Dda SILVA JA, JACOBS JW, KIRWAN JR et al.: Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis 2006; 65: 285-93.
7. HOES JN, JACOBS JW, BOERS M et al.: EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2007; 66: 1560-7.
8. van der GOES MC, JACOBS JW, BOERS M et al.: Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2010; 69: 1015-21.
9. GORTER SL, BIJLSMA JW, CUTOLO M et al.: Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010; 69: 1010-4.
10. van der GOES MC, JACOBS JW, BOERS M et al.: Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Ann Rheum Dis 2010; 69: 1913-9.
11. DURU N, van der GOES MC, JACOBS JW et al.: EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2013; 72: 1905-13.
12. BIJLSMA JW, JACOBS JW, BUTTGEREIT F: Glucocorticoids in the treatment of rheumatoid arthritis. Rheumatology 2013 (in press).
13. BUTTGEREIT F, DOERING G, SCHAEFFLER A et al.: Efficacy of modified-release versus stan-dard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet 2008; 371: 205-14.
14. BUTTGEREIT F, DOERING G, SCHAEFFLER A et al.: Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis. Ann Rheum Dis 2010; 69: 1275-80.
15. BUTTGEREIT F, MEHTA D, KIRWAN J et al.: Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). Ann Rheum Dis 2013; 72: 204-10.
16. THIELE S, ZIEGLER N, TSOURDI E et al.: Selective glucocorticoid receptor modulation maintains bone mineral density in mice. J Bone Miner Res 2012; 27: 2242-50.
17. BASCHANT U, FRAPPART L, RAUCHHAUS U et al.: Glucocorticoid therapy of antigen-induced arthritis depends on the dimerized glucocorticoid receptor in T cells. Proc Natl Acad Sci USA 2011; 108: 19317-22.
18. KLEIMAN A, HüBNER S, RODRIGUEZ PARKITNA JM et al.: Glucocorticoid receptor dimerization is required for survival in septic shock via suppression of interleukin-1 in macrophages. FASEB J 2012; 26: 722-9.
19. VANDEVYVER S, DEJAGER L, Vvan BOGAERT T et al.: Glucocorticoid receptor dimerization induces MKP1 to protect against TNF-induced inflammation. J Clin Invest 2012; 122: 2130-40.
20. VANDEVYVER S, DEJAGER L, TUCKERMANN J, LIBERT C: New insights into the anti-inflammatory mechanisms of glucocorticoids: an emerging role for glucocorticoid-receptor-mediated transactivation. Endocrinology 2013; 154: 993-1007.
21. RAUCHHAUS U, SCHWAIGER FW, PANZNER S: Separating therapeutic efficacy from glucocorticoid side-effects in rodent arthritis using novel, liposomal delivery of dexamethasone phosphate: long-term suppression of arthritis facilitates interval treatment, Arthritis Res Ther 2009; 11: R190.
22. RAUCHHAUS U, KINNE RW, POHLERS D et al.: Targeted delivery of liposomal dexamethasone phosphate to the spleen provides a persistent therapeutic effect in rat antigen-induced arthritis. Ann Rheum Dis 2009; 68: 1933-4.
23. BARRERA P, MULDER S, SMETSERS AI et al.: Long-circulating Liposomal Prednisolone versus Pulse Intramuscular Methylprednisolone in Patients with Active Rheumatoid Arthritis. ACR 2008. Abstract L10.
24. METSELAAR JM, WAUBEN MH, WAGENAAR-HILBERS JP, BOERMAN OC, STORM G: Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes. Arthritis Rheum 2003; 48: 2059-66.
25. METSELAAR JM, van den BERG WB, HOLTHUYSEN AE, WAUBEN MH, STORM G, van LENT PL: Liposomal targeting of glucocorticoids to synovial lining cells strongly increases therapeutic benefit in collagen type II arthritis. Ann Rheum Dis 2004; 63: 348-53.
26. van den HOVEN JM, VAN TOMME SR, METSELAAR JM, NUIJEN B, BEIJNEN JH, STORM G: Liposomal drug formulations in the treatment of rheumatoid arthritis. Mol Pharm 2011; 8: 1002-15.
27. ZIMMERMANN GR, AVERY W, FINELLI AL, FARWELL M, FRASER CC, BORISY AA: Selective amplification of glucocorticoid anti-inflammatory activity through synergistic multi-target action of a combination drug. Arthritis Res Ther 2009; 11: R12.
28. PAUL-CLARK MJ, MANCINI L, Ddel SOLDATO P, FLOWER RJ, PERRETTI M: Potent antiarthritic properties of a glucocorticoid derivative, NCX-1015, in an experimental model of arthritis, Proc Natl Acad Sci USA 2002; 99: 1677-82.
29. SPIES CM, BARTHOLOME B, BERKI T et al.: Membrane glucocorticoid receptors (mGCR) on monocytes are up-regulated after vaccination. Rheumatology 2007; 46: 364-5.
30. BARTHOLOME B, SPIES CM, GABER T et al.: Membrane glucocorticoid receptors (mGCR) are expressed in normal human peripheral blood mononuclear cells and up-regulated after in vitro stimulation and in patients with rheumatoid arthritis. FASEB J 2004; 18: 70-80.
31. TRYC AB, SPIES CM, SCHNEIDER U et al.: Membrane glucocorticoid receptor expression on peripheral blood mononuclear cells in patients with ankylosing spondylitis. J Rheumatol 2006; 33: 2249-53.
32. SPIES CM, SCHAUMANN DH, BERKI T et al.: Membrane glucocorticoid receptors are down regulated by glucocorticoids in patients with systemic lupus erythematosus and use a caveolin-1-independent expression pathway. Ann Rheum Dis 2006; 65: 1139-46.
33. STREHL C, GABER T, LöWENBERG M et al.: Origin and functional activity of the membrane-bound glucocorticoid receptor. Arthritis Rheum 2011; 63: 3779-88.
34. BRINKER AM, MA J, LIPSKY PE, RASKIN I: Medicinal chemistry and pharmacology of genus Tripterygium (Celastraceae). Phytochemistry 2007;68:732-66.
35. GOLDBACH-MANSKY R, WILSON M, FLEISCHMANN R et al.: Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial. Ann Intern Med 2009; 151: 229-40.